Omalizumab for chronic urticaria in Latin America

ConclusionOmalizumab is an effective treatment for patients with CU. It is necessary to conduct some future investigations where we can establish if 150 mg could be an option in developing countries.

http://link.springer.com/10.1186/s40413-016-0127-y

Source: World Allergy Organization Journal - November 22, 2016 Category: Allergy & Immunology Source Type: research